GO:0007521 muscle cell fate determination: Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007521 describes the cell fate determination process in which a cell becomes capable of differentiating autonomously into a muscle cell regardless of its environment, and once determined, this fate cannot be reversed [QuickGO definition].
• Muscle cell fate determination is a critical early step in myogenesis, cardiogenesis, and vascular smooth muscle development, and its dysregulation contributes to atherosclerosis, aortic aneurysm, and diabetic macroangiopathy [1,3,4,6].
• Single-cell and spatial multiomics have revealed that smooth muscle cells can undergo phenotypic switching to macrophage-like or other states, a process rooted in altered fate determination programs [1,3,7].
• Key transcription factors and signaling pathways, including ATF3, CD147-type I interferon signaling, and desmosomal components, regulate muscle cell fate decisions in development and disease [4,5,6].
• Optimization of cell fate determination is essential for cultivated muscle differentiation, with direct applications in cultured meat and regenerative medicine.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal interrogation of genes controlling muscle cell fate determination [2,4,8].
Description
Muscle cell fate determination (GO:0007521) is the developmental process by which a cell becomes committed to a muscle lineage, acquiring the capacity to differentiate autonomously into a muscle cell regardless of its environment, after which the fate cannot be reversed [QuickGO definition]. This process is fundamental to the formation of skeletal, cardiac, and smooth muscle tissues during embryogenesis and to the maintenance and repair of muscle tissues in adults. Understanding muscle cell fate determination is therefore central to developmental biology, regenerative medicine, and the study of diseases characterized by abnormal muscle cell plasticity, such as atherosclerosis and aortic aneurysm [1,4]. Recent advances in single-cell genomics and spatial multiomics have illuminated the heterogeneity of muscle cell states and the dynamic nature of fate transitions in both mouse and human tissues [1,3]. For example, single-cell genomics has identified a novel cell state during smooth muscle cell phenotypic switching with potential therapeutic targets for atherosclerosis, while spatial multiomics has revealed smooth muscle phenotypic transformation and metabolic reprogramming in diabetic macroangiopathy. These studies underscore that muscle cell fate determination is not a static event but a continuously regulated process that can be reactivated or dysregulated in disease. In this article, we integrate the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanisms, key genes, disease relevance, and experimental methods for studying muscle cell fate determination.
muscle cell fate determination At A Glance
| GO ID | GO:0007521 |
|---|---|
| GO term | muscle cell fate determination |
| Ontology | biological_process |
| Synonym | none |
| Definition | The cell fate determination process in which a cell becomes capable of differentiating autonomously into a muscle cell regardless of its environment; upon determination, the cell fate cannot be reversed. |
| Major function | Commitment of a cell to a muscle lineage, enabling autonomous differentiation into muscle cells. |
| Related processes | Myogenesis, cardiogenesis, smooth muscle phenotypic switching, cell fate commitment. |
| Disease relevance | Atherosclerosis, abdominal aortic aneurysm, diabetic macroangiopathy, cardiomyopathy. |
What Is GO:0007521?
According to the Gene Ontology, muscle cell fate determination (GO:0007521) is the cell fate determination process in which a cell becomes capable of differentiating autonomously into a muscle cell regardless of its environment; upon determination, the cell fate cannot be reversed. In simpler terms, it is the point of no return at which a cell commits to becoming a muscle cell, such as a skeletal myocyte, cardiomyocyte, or smooth muscle cell, and will proceed to differentiate even if removed from its normal surroundings. This term is a biological process and is distinct from later differentiation steps; it specifically captures the commitment event that establishes muscle cell identity.
Why Is muscle cell fate determination Important in Cell Biology?
Muscle cell fate determination is important because it governs the formation and maintenance of all muscle tissues and because its dysregulation underlies major human diseases. In atherosclerosis, smooth muscle cells can switch phenotypes to macrophage-like states, contributing to plaque progression, and single-cell genomics has identified a novel cell state during this switching that may serve as a therapeutic target. Similarly, in abdominal aortic aneurysm, spatiotemporal ATF3 expression determines vascular smooth muscle cell fate, linking fate determination directly to disease progression. In diabetic macroangiopathy, spatial multiomics has revealed smooth muscle phenotypic transformation and metabolic reprogramming, highlighting how fate changes contribute to vascular complications. Furthermore, desmosomes have been implicated in cell fate determination from cardiogenesis to cardiomyopathy, connecting cell adhesion structures to muscle fate decisions. Beyond disease, optimizing muscle cell fate determination is critical for cultivated muscle differentiation, with applications in food biotechnology and regenerative medicine. Thus, understanding GO:0007521 provides mechanistic insight into development, disease, and therapeutic innovation.
• Essential for embryonic development of skeletal, cardiac, and smooth muscle tissues.
• Dysregulation contributes to atherosclerosis through smooth muscle cell phenotypic switching.
• ATF3 expression determines vascular smooth muscle cell fate in abdominal aortic aneurysm.
• Spatial multiomics links smooth muscle phenotypic transformation to diabetic macroangiopathy.
• Desmosomal components influence cell fate determination in cardiogenesis and cardiomyopathy.
• ROS-activated CD147-type I interferon signaling drives smooth muscle cell fate transition in aortic aneurysm.
• Macrophage-like smooth muscle cells play a critical role in advanced atherosclerotic plaques.
• Enhancer-associated lncRNA-ITGA2 promotes vascular remodeling through ITGA2, implicating fate regulation.
• Optimization of cell fate determination is key for cultivated muscle differentiation.
• Provides a basis for CRISPR-based disease modeling and therapeutic target discovery.
What Happens During muscle cell fate determination?
Commitment and Competence
In simple terms: A cell first becomes able to respond to muscle-inducing signals, then commits to the muscle lineage.
Muscle cell fate determination begins with competence, during which a cell acquires the ability to respond to differentiation cues. This step involves the integration of extracellular signals and intrinsic transcription factor networks. In vascular smooth muscle cells, phenotypic switching is associated with changes in cell state that reflect altered fate determination programs. Single-cell genomics has revealed a novel cell state during smooth muscle cell phenotypic switching, indicating that commitment is a dynamic process with intermediate states. Similarly, in diabetic macroangiopathy, spatial multiomics has shown smooth muscle phenotypic transformation, suggesting that competence and commitment are influenced by metabolic reprogramming.
Transcriptional Regulation of Fate
In simple terms: Specific transcription factors turn muscle genes on or off to lock in the muscle identity.
Transcription factors play a central role in muscle cell fate determination by activating muscle-specific gene programs and repressing alternative lineages. ATF3 exhibits spatiotemporal expression that determines vascular smooth muscle cell fate in abdominal aortic aneurysm, demonstrating that a single transcription factor can direct fate decisions in disease contexts. Enhancer-associated lncRNA-ITGA2 promotes vascular remodeling through ITGA2, indicating that non-coding regulatory elements also contribute to fate control. These findings illustrate that fate determination is orchestrated by a combination of transcription factors and enhancer-associated regulators.
Signaling Pathways and Environmental Inputs
In simple terms: Signals from outside the cell, such as ROS and interferon, can push a cell toward a muscle fate or alter it.
Extracellular signals modulate muscle cell fate determination. ROS-activated CD147-type I interferon signaling drives vascular smooth muscle cell fate transition and abdominal aortic aneurysm progression, showing that oxidative stress and immune signaling intersect with fate decisions. Desmosomes, which are cell adhesion structures, have been implicated in cell fate determination from cardiogenesis to cardiomyopathy, suggesting that cell-cell contacts provide environmental inputs. These pathways demonstrate that fate determination is not cell-autonomous but responsive to the microenvironment.
Phenotypic Switching and Plasticity
In simple terms: Even after determination, muscle cells can change their state under certain conditions, which is important in disease.
Although determination is classically irreversible, muscle cells can undergo phenotypic switching in pathological settings. Single-cell genomics has identified a novel cell state during smooth muscle cell phenotypic switching with potential therapeutic targets for atherosclerosis in mouse and human. Re-analysis of single-cell transcriptomics revealed a critical role of macrophage-like smooth muscle cells in advanced atherosclerotic plaque. These studies indicate that fate determination programs can be reactivated or modified, contributing to disease progression.
Metabolic and Epigenetic Integration
In simple terms: Metabolism and epigenetic changes help stabilize the muscle fate.
Metabolic reprogramming accompanies smooth muscle phenotypic transformation in diabetic macroangiopathy, as revealed by spatial multiomics. This suggests that metabolic state is integrated with fate determination. Additionally, enhancer-associated lncRNA-ITGA2 promotes vascular remodeling, implying epigenetic regulation through enhancers. Together, these mechanisms reinforce the stability of the determined state and its susceptibility to perturbation.
Key Genes Involved in GO:0007521 muscle cell fate determination
The following genes and proteins have been experimentally implicated in muscle cell fate determination and related phenotypic switching, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATF3 | Transcription factor determining vascular smooth muscle cell fate | Spatiotemporal expression in abdominal aortic aneurysm |
| CD147 | Mediates ROS-activated type I interferon signaling in smooth muscle fate transition | Drives abdominal aortic aneurysm progression |
| ITGA2 | Enhancer-associated lncRNA target promoting vascular remodeling | Regulates vascular smooth muscle phenotype |
| Desmosomal components | Cell adhesion structures influencing cardiogenesis and cardiomyopathy | Implicated in cell fate determination |
| MYOD1 | Master transcription factor of skeletal myogenesis | Classic marker of muscle determination (generic knowledge, not cited) |
| MYF5 | Transcription factor involved in skeletal muscle determination | Generic knowledge, not cited |
| MYOG | Transcription factor promoting myocyte differentiation | Generic knowledge, not cited |
| NKX2-5 | Cardiac transcription factor | Generic knowledge, not cited |
| GATA4 | Cardiac transcription factor | Generic knowledge, not cited |
| TBX5 | Cardiac transcription factor | Generic knowledge, not cited |
| SRF | Serum response factor regulating muscle genes | Generic knowledge, not cited |
| MEF2C | Transcription factor in muscle differentiation | Generic knowledge, not cited |
| ACTA2 | Smooth muscle actin, marker of smooth muscle cells | Generic knowledge, not cited |
| MYH11 | Smooth muscle myosin heavy chain, marker of contractile smooth muscle | Generic knowledge, not cited |
| KLF4 | Transcription factor promoting smooth muscle phenotypic switching | Generic knowledge, not cited |
| TCF21 | Transcription factor in smooth muscle development | Generic knowledge, not cited |
| NOTCH1 | Signaling receptor influencing smooth muscle fate | Generic knowledge, not cited |
How Is muscle cell fate determination Regulated?
Muscle cell fate determination is regulated by a combination of transcription factors, signaling pathways, and epigenetic mechanisms. ATF3 exhibits spatiotemporal expression that determines vascular smooth muscle cell fate in abdominal aortic aneurysm, indicating that its levels and timing are critical. ROS-activated CD147-type I interferon signaling drives vascular smooth muscle cell fate transition, linking oxidative stress and immune signaling to fate regulation. Enhancer-associated lncRNA-ITGA2 promotes vascular remodeling through ITGA2, suggesting that enhancer activity and non-coding RNAs modulate fate decisions. Desmosomes contribute to cell fate determination from cardiogenesis to cardiomyopathy, highlighting the role of cell adhesion in this regulation. Additionally, metabolic reprogramming revealed by spatial multiomics in diabetic macroangiopathy indicates that metabolic pathways influence smooth muscle phenotypic transformation. These layers of regulation ensure that fate determination is robust yet adaptable to environmental cues.
muscle cell fate determination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATF3 | Abdominal aortic aneurysm | Knockout or overexpression in vascular smooth muscle cells |
| CD147 | Abdominal aortic aneurysm | Knockout or point mutation in smooth muscle cells |
| ITGA2 | Vascular remodeling | Knock-in or overexpression models |
| Desmosomal genes | Cardiomyopathy | Knockout in cardiomyocytes |
| KLF4 | Atherosclerosis | Overexpression or knockout in smooth muscle cells (generic knowledge, not cited) |
Atherosclerosis and Smooth Muscle Phenotypic Switching
Atherosclerosis is characterized by the accumulation of plaques in arteries, in which smooth muscle cells undergo phenotypic switching. Single-cell genomics has identified a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. Re-analysis of single-cell transcriptomics revealed a critical role of macrophage-like smooth muscle cells in advanced atherosclerotic plaque. These findings directly link muscle cell fate determination to atherosclerosis pathogenesis.
Abdominal Aortic Aneurysm and ATF3
Abdominal aortic aneurysm involves weakening of the aortic wall, in which vascular smooth muscle cell fate transitions contribute to disease. Spatiotemporal ATF3 expression determines vascular smooth muscle cell fate in abdominal aortic aneurysm. ROS-activated CD147-type I interferon signaling drives vascular smooth muscle cell fate transition and abdominal aortic aneurysm progression. Thus, fate determination pathways are central to aneurysm development.
Diabetic Macroangiopathy and Metabolic Reprogramming
Diabetic macroangiopathy is a vascular complication of diabetes. Spatial multiomics has revealed smooth muscle phenotypic transformation and metabolic reprogramming in diabetic macroangiopathy. This indicates that metabolic changes intersect with muscle cell fate determination in diabetes-associated vascular disease.
Cardiomyopathy and Desmosomes
Desmosomes have been implicated in cell fate determination from cardiogenesis to cardiomyopathy. This suggests that disruptions in desmosomal components can alter muscle cell fate decisions and contribute to cardiomyopathy.
From muscle cell fate determination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X drive smooth muscle fate switching? | Knockout in vascular smooth muscle cells [1,4] |
| Does a point mutation in gene Y alter fate determination? | Point mutation knock-in in myoblasts |
| Can overexpression of gene Z induce muscle fate? | Overexpression in progenitor cells |
| What is the spatiotemporal expression of ATF3? | Tagged knock-in reporter |
| How does CD147 signaling affect fate transition? | Knockout and rescue in smooth muscle cells |
| What is the role of desmosomes in cardiogenesis? | Knockout in cardiomyocyte precursors |
How to Study the muscle cell fate determination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Single-cell RNA-seq | Cell state heterogeneity and fate transitions | Identifying novel smooth muscle cell states [1,7] |
| Spatial multiomics | Spatial distribution of transcripts and metabolites | Studying phenotypic transformation in diabetic macroangiopathy |
| CRISPR knockout | Loss-of-function effects on fate determination | Testing ATF3 and CD147 roles [4,6] |
| CRISPR knock-in | Precise mutation or tag introduction | Studying point mutations in fate genes |
| Overexpression | Gain-of-function effects | Testing ITGA2 and lncRNA roles |
| Immunofluorescence | Protein localization and expression | Validating fate markers in tissues |
| Flow cytometry | Cell surface marker expression | Sorting muscle cell populations (generic knowledge, not cited) |
Single-Cell Genomics
Single-cell genomics enables the identification of novel cell states during muscle cell phenotypic switching. This method has been used to reveal a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. It is also instrumental in re-analysis of single-cell transcriptomics to uncover macrophage-like smooth muscle cells in advanced atherosclerotic plaque.
Spatial Multiomics
Spatial multiomics combines spatial transcriptomics and metabolomics to reveal smooth muscle phenotypic transformation and metabolic reprogramming in diabetic macroangiopathy. This approach allows researchers to study muscle cell fate determination in situ, preserving tissue architecture.
Genetic Knockout and Knock-in Models
CRISPR-based knockout and knock-in models are used to test the causal role of genes in muscle cell fate determination. For example, ATF3 spatiotemporal expression has been studied using genetic models in abdominal aortic aneurysm. CD147 signaling has been interrogated using knockout approaches. Enhancer-associated lncRNA-ITGA2 has been studied using overexpression and knock-in models.
Cell Fate Optimization Assays
Optimization of cell fate determination for cultivated muscle differentiation involves systematic testing of differentiation protocols and genetic factors. These assays measure the efficiency and stability of muscle cell commitment.
How CRISPR Can Be Used to Study GO:0007521 muscle cell fate determination
Knockout
CRISPR knockout is used to delete genes involved in muscle cell fate determination to assess loss-of-function phenotypes. For example, knockout of ATF3 or CD147 in vascular smooth muscle cells can reveal their roles in fate transition and disease progression [4,6]. Knockout of desmosomal genes in cardiomyocytes can test their role in cardiogenesis.
Point Mutation
CRISPR point mutation introduces specific nucleotide changes to model disease-associated variants or to dissect functional domains. This approach can be applied to genes such as ATF3 or CD147 to determine which residues are critical for fate determination [4,6].
Knock-in
CRISPR knock-in allows the insertion of reporter tags or human disease alleles. Tagged knock-in of ATF3 can be used to track its spatiotemporal expression during fate determination. Knock-in of ITGA2 enhancer elements can test their regulatory role.
Overexpression
CRISPR activation or cDNA overexpression is used to test gain-of-function effects on muscle cell fate. Overexpression of lncRNA-ITGA2 promotes vascular remodeling through ITGA2, demonstrating the utility of this approach. Overexpression of transcription factors can also drive fate commitment in progenitor cells.
How EDITGENE Supports muscle cell fate determination Research
Researchers studying muscle cell fate determination-related genes often need to determine whether a candidate gene is causally involved in fate commitment, phenotypic switching, or disease progression. EDITGENE provides comprehensive CRISPR-based services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for muscle cell fate determination research.
Frequently Asked Questions About muscle cell fate determination
What is muscle cell fate determination GO:0007521?
GO:0007521 is the cell fate determination process in which a cell becomes capable of differentiating autonomously into a muscle cell regardless of its environment; upon determination, the cell fate cannot be reversed [QuickGO definition].
What genes are involved in muscle cell fate determination?
Genes such as ATF3, CD147, ITGA2, and desmosomal components have been implicated in muscle cell fate determination and related phenotypic switching [4,5,6,8].
How is muscle cell fate determination studied?
It is studied using single-cell genomics, spatial multiomics, CRISPR knockout and knock-in models, and cell fate optimization assays [1,2,3,4].
Why is muscle cell fate determination important in atherosclerosis?
Single-cell genomics has identified a novel cell state during smooth muscle cell phenotypic switching with potential therapeutic targets for atherosclerosis, linking fate determination to plaque progression.
What role does ATF3 play in muscle cell fate?
Spatiotemporal ATF3 expression determines vascular smooth muscle cell fate in abdominal aortic aneurysm.
How does CD147 signaling affect muscle cell fate?
ROS-activated CD147-type I interferon signaling drives vascular smooth muscle cell fate transition and abdominal aortic aneurysm progression.
What is the connection between desmosomes and muscle cell fate?
Desmosomes have been implicated in cell fate determination from cardiogenesis to cardiomyopathy.
Can muscle cell fate determination be reversed?
By definition, upon determination the cell fate cannot be reversed, but phenotypic switching can occur in disease states such as atherosclerosis [1,7].
What methods reveal smooth muscle phenotypic transformation?
Spatial multiomics reveals smooth muscle phenotypic transformation and metabolic reprogramming in diabetic macroangiopathy.
How can CRISPR help study muscle cell fate determination?
CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of genes such as ATF3, CD147, and ITGA2 in fate determination [4,6,8].
Conclusion
Muscle cell fate determination (GO:0007521) is a fundamental biological process that commits cells to a muscle lineage and underlies the development and maintenance of skeletal, cardiac, and smooth muscle tissues. Its dysregulation is increasingly recognized as a driver of vascular diseases, including atherosclerosis, abdominal aortic aneurysm, and diabetic macroangiopathy, through mechanisms involving transcription factors such as ATF3, signaling pathways such as CD147-type I interferon, and enhancer-associated regulators like lncRNA-ITGA2 [1,3,4,6,8]. Advances in single-cell and spatial multiomics have illuminated the heterogeneity and plasticity of muscle cell states, providing new therapeutic targets [1,3,7]. CRISPR-based models are indispensable for causal interrogation of these genes, and EDITGENE offers a comprehensive suite of services to support such research.
References
- 1. Pan H et al.. 2020. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human.. Circulation 142(21):2060-2075 PMID: 32962412
- 2. Melzener L et al.. 2024. Optimisation of cell fate determination for cultivated muscle differentiation.. Commun Biol 7(1):1493 PMID: 39532984
- 3. Qian Y et al.. 2024. Spatial multiomics atlas reveals smooth muscle phenotypic transformation and metabolic reprogramming in diabetic macroangiopathy.. Cardiovasc Diabetol 23(1):358 PMID: 39395983
- 4. Wen Y et al.. 2024. Spatiotemporal ATF3 Expression Determines VSMC Fate in Abdominal Aortic Aneurysm.. Circ Res 134(11):1495-1511 PMID: 38686580
- 5. Moazzen H et al.. 2023. Desmosomes in Cell Fate Determination: From Cardiogenesis to Cardiomyopathy.. Cells 12(17) PMID: 37681854
- 6. Zhong F et al.. 2025. ROS-activated CD147-type I interferon signaling axis drives vascular smooth muscle cell fate transition and abdominal aortic aneurysm progression.. Redox Biol 86:103780 PMID: 40803247
- 7. Gong X et al.. 2024. Re-analysis of single-cell transcriptomics reveals a critical role of macrophage-like smooth muscle cells in advanced atherosclerotic plaque.. Theranostics 14(4):1450-1463 PMID: 38389849
- 8. Guo X et al.. 2025. Enhancer-Associated LncRNA-ITGA2 Promotes Vascular Remodeling Through ITGA2.. Circ Res 136(12):1610-1628 PMID: 40321134
